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Abstract
Background: There is an estimate of three to five million people who inject drugs living in Asia. Unsafe injecting
drug use is a major driver of both the HIV and hepatitis C (HCV) epidemic in this region, and an increase in
incidence among people who inject drugs continues. Although harm reduction is becoming increasingly accepted,
a largely punitive policy remains firmly in place, undermining access to life-saving programmes. The aim of this
study is to present an overview of key findings on harm reduction in Asia based on data collected for the Global
State of Harm Reduction 2014.
Methods: A review of international scientific and grey literature was undertaken between May and September
2014, including reports from multilateral agencies and international non-governmental organisations. A qualitative
survey comprising open-ended questions was also administered to civil society, harm reduction networks, and
organisations of people who use drugs to obtain national and regional information on key developments in harm
reduction. Expert consultation from academics and key thinkers on HIV, drug use, and harm reduction was used to
verify findings.
Results: In 2014, 17 countries in Asia provide needle and syringe programmes (NSP) provision and 15 opioid
substitution therapy (OST). It is estimated that between 60 and 90 % of people who use drugs in Asia have HCV;
however, treatment still remains out of reach due to cost barriers. TB testing and treatment services are yet to be
established for key populations, yet nearly 15 % of the global burden of new cases of HIV-TB co-infection are
attributed to southeast Asia. Eighteen percent of the total number of people living with HIV eligible for antiretroviral
treatment (ART) accessed treatment. Only Malaysia and Indonesia provide OST in prison, with no NSP provision in
prisons in the region.
Conclusion: To reduce HIV and viral hepatitis risk among people who inject drugs, there is a necessity to significantly
increase harm reduction service provision in Asia. Although there has been progress, work still needs to be done to
ensure an appropriate and enabling environment. At present, people who inject drugs are extremely difficult to reach;
structural and legal barriers to services must be reduced, integrated holistic services introduced, and further research
undertaken.
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Background
Injecting drug use has been documented in at least 158
countries and territories worldwide [1]. Although harm
reduction is becoming increasingly accepted, further ini-
tiatives are vital for its successful implementation in
Asia. Asia is one of the regions particularly affected by
HIV among people who inject drugs [2], with an esti-
mated three to five million people who inject drugs liv-
ing in the region [3]. HIV prevalence among people who
use drugs ranges from over 40 % in the Philippines [4]
to under 10 % in China [5]. Asia, however, remains a re-
gion which relies upon an overly-punitive response to
drugs, for example it is still one of the few areas of the
globe that continue to implement the death penalty for
drug offenses, and 11 countries continue to use compul-
sory centres for people who use drugs as their primary
approach to treatment [3]. These types of services have
been shown to be both ineffective [6, 7] and unethical
[8], yet countries such as Cambodia, Thailand, and
Vietnam have yet to amend laws relating to detention
centres.
In places where harm reduction has been brought to
sufficient scale and quality, it has had a significant im-
pact in reducing HIV transmission. For example, Nepal,
which was an early implementer of harm reduction in
Asia, saw rates of HIV prevalence decline drastically
from 68 % in 2002 to 6.3 % in 2011 [3]. In a study
undertaken in Southwest China, the HIV incident rate
among people who inject drugs dropped significantly
from 2.5 to 0.6 cases per 100 person-years after the im-
plementation of harm reduction strategies including
NSP, OST, counselling, and condom promotion [9]. And
a further study in Taiwan, among people who inject
drugs released from prison, also found a decrease in
HIV incidence from 18.2 % in 2005 to 0.3 % in 2010, as-
sociated with attendance at methadone clinics and fre-
quency of NSP attendance [10].
Although the evidence for harm reduction, particularly
the use of NSP, OST, HIV testing and counselling and
anti-retroviral therapy as recommended by the World
Health Organization (WHO), United Nations Office on
Drugs and Crime (UNODC) and the Joint United Na-
tions Programme on HIV and AIDS (UNAIDS) [11], has
been widely acknowledged as a best practice approach,
there are still countries in Asia where a primarily puni-
tive policy and legal environment blocks access for
people who use drugs to these services, and provision is
at best lacking and at worst non-existent.
This paper looks at harm reduction responses in Asia
focusing on the impact a lack of services can have on
HIV, viral hepatitis, and TB epidemics. Using figures
from the Global State of Harm Reduction report 2014
[12] (see Additional file 1: Table S1), this paper will illus-
trate the ways in which policy has been successfully
translated into practice, countries which have struggled
to implement harm reduction irrespective of policy deci-
sions, and places in which punitive regimes and moral
concerns have overruled empirical evidence increasing
both risk and transmission of viruses among people who
inject drugs.
Methods
The basis of the findings from this paper is derived from
the Global State of Harm Reduction 2014 report [12].
Harm Reduction International has been mapping the re-
sponse to drug-related HIV and hepatitis C epidemics
around the world since 2008. The information presented
in the 2014 report has been gathered using existing data
sources, including research papers and reports from
multilateral agencies, international non-governmental
organisations, civil society and harm reduction networks,
organisations of people who use drugs, and expert and
academic opinion from those working on HIV, drug use,
and harm reduction. The biennial report integrates up-
dated information on harm reduction services, including
needle and syringe programmes (NSPs) and opioid sub-
stitution therapy (OST) provision, harm reduction ser-
vices in the prison setting, access to antiretroviral
therapy for people who inject drugs; regional overdose
responses, policy developments, civil society develop-
ments, and information relating to funding for harm re-
duction. A review of international scientific and grey
literature was undertaken between May and September
2014. A qualitative survey, comprising open-ended ques-
tions, was administered alongside this to civil society,
harm reduction networks, and organisations of people
who use drugs to obtain national and regional informa-
tion on key developments in harm reduction. A narra-
tive analysis was undertaken to synthesise findings, and
expert consultation from academics and key thinkers on
HIV, drug use, and harm reduction was used to peer-
review and verify findings.
Results
HIV epidemiology
Additional file 1: Table S1 provides epidemiology from
2014 of HIV, viral hepatitis, and harm reduction re-
sponses in Asia. The average rate of HIV prevalence
among people who inject drugs in Asia is 15.46 % [12].
HIV among this key population has increased in six
countries (Cambodia, Indonesia, Malaysia, Philippines,
Taiwan, and Thailand) since 2012 by an average of
7.75 % [12, 13]. However, the greatest growth can be
seen in the Philippines, where a 28 % increase in HIV
among people who inject drugs was seen between 2012
and 2014 [12, 13]. The HIV epidemic in the Philippines
has been steadily growing, and since 2008, has risen by
40 % among people who inject drugs [1, 12, 14, 15].
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Given the estimated number of people who inject drugs
in the Philippines (mean average 14,456), there is a dis-
tinct lack of harm reduction service provision, with only
three NSP sites in operation [13] and no OST provision.
The lowest HIV prevalence rates in Asia can be seen in
Bangladesh, with just 1.1 % of people who inject drugs
[16] and 88 NSP and three OST sites in operation as of
2014. This highlights the relative coverage and impact
the early implementation of harm reduction services can
have.
Hepatitis C and B epidemiology
In Japan, hepatitis C prevalence among people who in-
ject drugs is 64.8 % [17], and 54 % [17] in the Republic
of Korea, yet still no services exist for this marginalised
group. Thailand, Pakistan, Nepal, and Macau continue
to have over an 80 % hepatitis C prevalence among
people who inject drugs [17, 18]. It is important to note
that this information is often not regularly collected,
meaning data, aside from Macau, dates from prior to
2003. In Asia alone, approximately 2.6 million people
(range 1.8–3.6 million) are living with hepatitis C [17],
with an average prevalence rate among people who in-
ject drugs at 60.7 % [12]. Significant efforts have been
made by civil society organisations and people who use
drugs in Indonesia to scale up the government response
to hepatitis C treatment, with a set of guidelines becom-
ing available in 2014 laying out plans to integrate hepa-
titis C treatment into national surveillance among
people who inject drugs as of 2015 [19]. However, on
the whole, hepatitis treatment still remains out of reach
for most people due to exorbitant prices, and urgent
measures are needed to ensure that access to diagnosis
and treatment improves.
ART uptake among people who inject drugs
Although there is antiretroviral provision (antiretroviral
treatment (ART)) in Asia, more than two-thirds of
people who inject drugs do not know their HIV status
[3], and only 18 % of people living with HIV eligible for
treatment access it in this region [3]. This may be attrib-
uted to barriers such as stigmatisation by healthcare
staff, a lack of confidentiality, and no HIV testing offered
within harm reduction settings [20]. Studies providing
evidence of the benefits of integrating OST, HIV testing
and counselling, and ART in places such as Vietnam are,
however, helping to support and promote the integration
of these services through demonstrating higher retention
rates than drug users who do not receive integrated ser-
vice provision [21]. Joint service provision within a harm
reduction setting is therefore imperative to ensure
people who inject drugs access ART.
TB among people who inject drugs
Asia accounts for nearly 15 % of the global burden of
new cases of HIV-TB co-infection, [22] yet data on TB
for people who inject drugs is sparse. Individual studies,
however, indicate a disproportionate prevalence of TB
among people who inject drugs, with Malaysia reporting
TB-HIV co-infection for detainees in closed settings,
such as prisons and drug rehabilitation centres, increas-
ing from six to 1477 cases between 1990 and 2013 [23,
24]. Although TB treatment is integrated into HIV pro-
grammes in Bhutan, Cambodia, India, Indonesia, and
Nepal, it is unknown whether such services are designed
for people who inject drugs, and there is still a lack of




Although 19 countries in Asia explicitly include harm
reduction in their national plans and drug policies, the
existence does not necessarily equate to provision of an
adequate response in either scope or quality. Harm re-
duction interventions in the form of NSP and OST have
yet to be established in six countries within Asia. And al-
though injecting drug use is common in prisons in the
region [26, 27], only Malaysia and Indonesia provide
OST in this setting, with no NSP available. Cambodia’s
Drug Control Law 2012 states that a person who injects
drugs and is arrested for a drug-related offence should
be referred to treatment and related services [28], yet
this legal provision of referral is often not implemented
[29]. Other countries have seen improvements through
passing legal reforms, such as Singapore, who in 2013
passed a law allowing those facing the death penalty the
opportunity to ask for resentencing, with nine prisoners
applying having their sentences reduced to life imprison-
ment rather than death [30].
Malaysia is perhaps one of the best examples in Asia
in terms of the adoption and acceptance of harm reduc-
tion, with signs of increasing political commitment to a
gradual shift away from a punitive approach to a volun-
tary, rights-based approach to drug treatment [25].
Malaysia has transformed eight compulsory detention
centres into voluntary cure and care centres or clinics,
widely praised as best practice for the region [3].
Malaysia has also increased its OST provision in prisons,
expanding from one site in 2008 to 18 by 2013 [23], and
its NSP site provision by 431 between 2012 and 2014
[12, 13]. A reduction in HIV prevalence among people
who inject drugs is yet to be seen in this country; how-
ever, with continued commitment and increasing imple-
mentation of services, 18.9 % [23] of people who inject
drugs currently living with HIV should steadily decrease.
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Thanks to various civil society projects which have
been initiated in Asia, a successful response to HIV, viral
hepatitis, and TB among people who use drugs is grad-
ually becoming more feasible. Asia Action, a European
Commission funded project, has supported AIDS Care
China to scale up naloxone training and dissemination
among people who inject drugs [25]; in Cambodia, work
with police officers to offer a more enabling environ-
ment and reduce human rights violations against drug
users is underway [28], and research documenting the
implementation of Indonesia’s 2011 diversion policy,
which stipulates that people arrested on drug-related of-
fences with personal possession under a stated weight
should be referred to treatment rather than imprisoned,
is in process [31]. The Asian Network of People who
Use drugs (ANPUD), representing the voices of commu-
nities of people who use drugs in the region, have also
played an important role in advocating for evidence-
based changes in punitive drug laws and policies [25].
This work has given an overview of the harm reduc-
tion approaches in Asia synthesising available evidence.
There are, however, limitations to the data. In Asia, HIV
prevalence rates can range from over 40 % in countries
such as Pakistan [32] to less than 2 % in places such as
Macau [33]. However, national figures can often hide
significant regional and sub-national variations. For ex-
ample, national figures for HIV prevalence among
people who inject drugs appear to be declining in
Indonesia from 42.5 % in 2010 [34, 35] to 36.4 % in 2012
[36], yet in urban centres like Jakarta and Surabaya, HIV
prevalence estimates were 56.4 and 48.8 %, respectively
[37]. Other limitations to the data include only works
produced in English and the omission of quality criteria
to grade both published and grey literature.
Conclusion
Harm reduction interventions in Asia are often hindered
by a largely punitive policy, poor service provision, a lack
of human resources and funding mechanisms, and poor
service integration [38], all of which serve to undermine
access to life-saving harm reduction programmes. The
United Nations 2011 political declaration on HIV/AIDS
targets to reduce the transmission of HIV among people
who inject drugs by 50 % by 2015, thus becomes in-
creasingly unrealistic, and unsafe injecting practices
continue.
With high rates of hepatitis C among people who in-
ject drugs in Asia, this paper highly recommends greater
integration of hepatitis C prevention, education, testing,
and treatment services for drug users, alongside ART
and OST provision integrated not only in community
settings, but also in custodial settings. An increase in
harm reduction services is also vital to reduce the steady
HIV incidence among this marginalised and stigmatised
group.
As several international donors are gradually with-
drawing support [25], it is a worrying fact that harm re-
duction services currently running may be adversely
affected. To ensure this does not happen, rigorous as-
sessments detailing the adequacy of national funding to
support these initiatives are imperative, further work on
scaling up harm reduction programmes necessary, and
structural barriers reduced to ensure no drug user gets
left behind.
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